Doctors Revision

Aminoglycosides, Sulphonamides and Trimethoprim

Text size
On this page

Overview

Aminoglycosides in detail

Aminoglycosides bind the 30S ribosomal subunit, misreading mRNA and inserting wrong amino acids into the growing peptide — bactericidal concentration-dependent killing with a marked post-antibiotic effect. They are polar molecules with poor oral absorption (given IV/IM, except for bowel decontamination), negligible CSF penetration, and no activity against anaerobes (they need oxygen-dependent uptake into the bacterial cell).

Scroll the table sideways on a smaller screen.

The aminoglycosides: dose, indications, adverse effects, contraindications, counselling
DrugAdult dose (usual)Paediatric doseMain indicationsSide & adverse effectsContraindications & cautionsCounselling / monitoring
Gentamicin (Access)Once-daily dosing: 5–7 mg/kg IV/IM daily (per local protocol); traditional dosing 80 mg q8h adjusted to levelsNeonatal sepsis: 3–5 mg/kg once daily (age/weight bands per protocol); child: 5–7 mg/kg once dailyEmpiric Gram-negative sepsis, neonatal sepsis (with ampicillin/benzylpenicillin), pyelonephritis, endocarditis synergy (with beta-lactam), pelvic inflammatory diseaseNephrotoxicity (non-oliguric AKI, usually reversible), ototoxicity (vestibular > cochlear — imbalance, tinnitus, high-tone deafness, often irreversible), neuromuscular blockade at high dosePregnancy (fetal VIIIth-nerve damage — use only if life-threatening), myasthenia gravis (worsens block), renal impairment (level-guided dosing), avoid with loop diuretics and other nephro/ototoxinsReport dizziness, ringing or hearing change immediately; ensure hydration; levels taken around the dose; ototoxicity can be permanent
Amikacin (Access)15 mg/kg once daily IV/IM; max 1.5 g/day15 mg/kg once dailySevere Gram-negative infection resistant to gentamicin (many gentamicin-resistant organisms remain amikacin-sensitive), multidrug-resistant TB (injectable second-line, specialist), nocardiosisSame class profile; somewhat lower resistance rates; ototoxicity especially after prolonged useAs gentamicinLevels mandatory; audiometry on prolonged courses
StreptomycinTB (combination): 15 mg/kg IM once daily, max 1 g; brucellosis/plague/tularemia regimens per protocolTB: 15 mg/kg IM once dailySecond-line injectable anti-TB drug (with isoniazid/rifampicin in retreatment per national TB guidelines), brucellosis (combination), plagueVestibular toxicity (dose/duration-related), nephrotoxicity, injection-site painPregnancy; renal impairment; vestibular diseaseReport unsteadiness early; IM injections are prolonged courses
Neomycin (topical/oral, not absorbed)Hepatic encephalopathy gut decontamination: 1 g 6-hourly orally ×5–7 days; topical eye/skin per preparationNot for systemic use in children except specialist gut decontaminationOral/topical only — pre-operative bowel preparation, hepatic encephalopathy adjunct, superficial infectionOral: diarrhoea, C. difficile; prolonged gut use can still cause deafness in renal impairment (absorbed fraction)Never systemic IV/IM (systemic nephro/ototoxicity); renal impairment; bowel obstructionOral course is short; report hearing change on long use

Synergy — the classic combinations

  • Aminoglycoside + beta-lactam is synergistic in endocarditis and Gram-negative sepsis: the beta-lactam opens the cell wall, improving aminoglycoside entry. (Never mix them in the same syringe — chemical inactivation.)
  • Classic pairings: ampicillin/benzylpenicillin + gentamicin for enterococcal or neonatal sepsis; cloxacillin + gentamicin for staphylococcal endocarditis.

Nephro- and ototoxicity: monitoring

  1. Check renal function (creatinine, eGFR) before starting and every 2–3 days on therapy.
  2. Serum levels: for once-daily dosing, a random level ~6–14 h after the dose is compared with a nomogram, or trough before the next dose — follow your facility's protocol. Aim for a high peak and an undetectable trough.
  3. Clinical surveillance: daily ask about tinnitus, fullness, balance; bedside testing of hearing (whisper/finger-rub) on prolonged courses.
  4. Neuromuscular blockade: aminoglycosides potentiate blockers — caution in myasthenia gravis and around surgery/ventilation.

Sulphonamides, trimethoprim and cotrimoxazole

The sulphonamides (synthetic, not true antibiotics) are p-aminobenzoic acid (PABA) analogues that competitively inhibit dihydropteroate synthetase, blocking folate synthesis; trimethoprim inhibits the next enzyme, dihydrofolate reductase (DHFR). Humans obtain folate from food, so the block is selectively toxic. Alone, each drug is bacteriostatic; combined as cotrimoxazole (co-trimoxazole) in the classic 5:1 ratio (sulphamethoxazole 400 mg + trimethoprim 80 mg per tablet) they become bactericidal — sequential blockade of one pathway, the same logic as multi-drug TB therapy.

Figure 1: Two panels — aminoglycosides binding the 30S ribosomal subunit to cause misreading, and the bacterial folate pathway blocked by sulphonamides and trimethoprim in two sequential steps
Figure 1: Left — aminoglycosides bind the 30S subunit, corrupting translation. Right — sulphonamides and trimethoprim sequentially block bacterial folate synthesis.

Scroll the table sideways on a smaller screen.

Folate-pathway agents compared
DrugAdult dose (usual)Paediatric doseMain indicationsSide & adverse effectsContraindications & cautionsCounselling
Cotrimoxazole (co-trimoxazole) (Access)UTI: 960 mg 12-hourly ×3 days. Dysentery: 960 mg 12-hourly ×5 days. Pneumocystis (PCP): high-dose 120 mg/kg/day in 3–4 divided doses ×21 days. HIV prophylaxis: 960 mg daily or 3×/week6–12 mg TMP/kg/day divided 12-hourly (per indication); PCP 15–20 mg TMP/kg/dayUTI and dysentery, PCP treatment and prophylaxis, HIV/OI prophylaxis (with isoniazid per national guidelines), skin/soft-tissue infection, brucellosis/toxoplasmosis (combination)Skin eruptions incl. SJS/TEN (most feared — any rash: stop the drug), nausea, marrow suppression (folate antagonism), hyperkalaemia (trimethoprim blocks renal ENaC like a potassium-sparing diuretic), photosensitivity, crystalluriaSulphonamide allergy or prior SJS/TEN; pregnancy (teratogenic folate antagonism — avoid first trimester; give folate if essential); severe renal impairment; avoid in G6PD-deficiency crisis (haemolysis) and with methotrexate, warfarin, phenytoin, ACE inhibitors in renal impairmentDrink plenty of fluids; stop immediately for any rash, mouth ulcers or sore throat; expect mild nausea; report palpitations/weakness (high K⁺) on high-dose or renal disease
Trimethoprim alone200 mg 12-hourly ×3 days (uncomplicated UTI, per local resistance)2 mg/kg 12-hourlyUncomplicated lower UTI where local E. coli resistance is lowSame profile but less severe; hyperkalaemia; marrow suppression (megaloblastic changes)As above; renal impairment (dose-adjust)Complete short course; report rash or unusual bruising
Silver sulfadiazine (topical)Burns dressing 1% cream daily/bdAs adult, topicalSecond/third-degree burns (broad cover incl. Pseudomonas), leg ulcers (short term)Local rash, transient neutropenia/leucopenia on large-area use, kernicterus risk in newborn (absorbed sulphonamide)Sulphonamide allergy; neonates; large burns in G6PD deficiencyReport spreading rash; painless peeling skin is a red flag

Cotrimoxazole in detail

Cotrimoxazole deserves its own section because of its outsized role in HIV care and common syndromes:

  • HIV prophylaxis: 960 mg daily (or thrice weekly) prevents PCP, toxoplasmosis and bacterial infections in eligible patients per national ART guidelines; co-trimoxazole prophylaxis is one of the highest-impact, cheapest interventions in HIV medicine.
  • PCP (Pneumocystis pneumonia): treatment is high-dose (15–20 mg/kg/day of the trimethoprim component) for 21 days — oral in mild disease, IV in severe; add prednisolone when PaO₂ is low, per protocol.
  • Resistance: high E. coli resistance in many regions has eroded its role in empiric UTI — check local antibiograms; in dysentery and PCP it retains strong activity.
  • SJS/TEN warning: sulphonamide hypersensitivity is the classic trigger of Stevens–Johnson syndrome and toxic epidermal necrolysis. Any mucosal involvement, blistering or spreading rash on cotrimoxazole = stop the drug, admit, and never re-challenge.

Interactions and counselling

Scroll the table sideways on a smaller screen.

Clinically important interactions
DrugInteracting agentEffectAction
AminoglycosidesLoop diuretics (furosemide), vancomycin, amphotericin B, platinum agentsAdditive nephro- and ototoxicity — deafness riskAvoid combination; if unavoidable, monitor renal function and hearing closely
AminoglycosidesNeuromuscular blockers (suxamethonium, vecuronium)Prolonged paralysis / respiratory depressionCaution peri-operatively and in ITU; reverse block before extubation
Cotrimoxazole / trimethoprimWarfarinMarked INR rise → bleedingAvoid or monitor INR every 2–3 days
Cotrimoxazole / trimethoprimMethotrexateAdditive DHFR inhibition → severe marrow suppressionContraindicated together
Cotrimoxazole / trimethoprimPhenytoin, sulphonylureas (glibenclamide), digoxinReduced clearance → phenytoin toxicity, hypoglycaemia, raised digoxinMonitor levels/clinical effect; counsel on hypoglycaemia
Cotrimoxazole / trimethoprimACE inhibitors, ARBs, spironolactone, potassium supplementsAdditive hyperkalaemia (trimethoprim blocks ENaC)Avoid in renal impairment; check potassium
SulphonamidesOther sulphonamides/sulfonylureas ("sulfa" drugs), thiazides"Sulfa allergy" cross-reactions — but sulphonamide antibiotics are distinct from non-antibiotic sulfa (e.g., furosemide) for most patientsDocument carefully; true antibiotic-sulphonamide SJS/TEN is an absolute contraindication to all sulphonamide antibiotics

Clinical scenarios

Scenario 1 — Neonatal sepsis on the postnatal ward

A 3-day-old, born at home, presents with poor feeding, hypothermia and fast breathing. You start the UCG empiric regimen: ampicillin plus gentamicin (gentamicin 3–5 mg/kg once daily by weight band). Gentamicin covers the Gram-negative enteric flora that colonise the birth canal; ampicillin covers Group B streptococcus, Listeria and pneumococcus. You take blood cultures first, check the mother's syphilis/HIV status, and arrange gentamicin level monitoring. On day 3 the cultures grow Escherichia coli sensitive to gentamicin — you continue, reassessing daily, and stop ampicillin (de-escalation).

Scenario 2 — The dizzy patient on gentamicin

A 67-year-old on day 6 of gentamicin for pyelonephritis reports new unsteadiness and a "full" feeling in the ears. Gentamicin preferentially damages the vestibular division — the onset of imbalance after several days is classic ototoxicity, and it may be irreversible. You stop the drug (switch to a safer alternative guided by sensitivities), document the adverse drug reaction, and check that the renal function had not quietly deteriorated — the accumulation that caused it. Teaching point: ask about hearing and balance daily; the patient rarely volunteers it until late.

Scenario 3 — HIV clinic: starting cotrimoxazole prophylaxis

A newly diagnosed 34-year-old with CD4 180 cells/µL starts ART; per national guidelines you also start cotrimoxazole 960 mg daily to prevent PCP and bacterial infections. You counsel: take with food if nauseated, drink well, and stop immediately for any rash or mouth ulcers — sulphonamides can cause a dangerous skin reaction (SJS). If she were on warfarin or had renal disease with ACE-inhibitor therapy, you would reconsider or monitor potassium and INR.

Key points

References

  • WHO AWaRe Antibiotic Book, 2022/2023 — UTI, dysentery and PCP regimens (Library reference.)
  • Uganda Clinical Guidelines 2023: neonatal sepsis, UTI and HIV/OI prophylaxis chapters (Library reference.)
  • Uganda Essential Medicines and Health Supplies List 2023 (Library reference.)
  • Katzung's Basic & Clinical Pharmacology — aminoglycoside and sulfonamide chapters (Library reference.)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)
  • Uganda National ART/PMTCT guidelines — cotrimoxazole prophylaxis schedule (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.

For education only. Doses change with guideline updates — always verify against the current Uganda Clinical Guidelines, the EMHSLU 2023 and your facility formulary before prescribing.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top